ATANIS Biotech completes capital increase to improve the diagnosis of allergies
Summary
ATANIS Biotech aims to simplify and improve the current standard of care for the diagnosis of allergies. With proceeds from the financing, ATANIS will accelerate its product development, scale its services for pharma/biotech customers, and implement its go-to-market strategy.ATANIS is developing its FAST-PASE technology, offering lab testing solutions to mimic allergic reactions safely in a test tube. The customer base ranges from highly established industrial partners to individual research groups.In March, ATANIS moved its operational premises to a new location in Bern enabling the company to increase its sample processing capacity. Additionally, three new team members were appointed, bolstering their commercialization capabilities: Doris Corpataux will lead the companys regulatory strategy, Nathan Laborde will be responsible for implementing quality processes, and Bertrand Landel will spearhead commercial and marketing operations.The company has now completed a significant capital increase. Additional investments came from experienced private biotech investors.At ATANIS, our mission is to revolutionize the way allergies are diagnosed and thereby improve treatment success and quality of life for patients, said Chief Executive Officer Jean-Pierre Kinet, M.D.